WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will present today its plans for driving the continued strong commercial performance of its existing multiple sclerosis (MS) treatments, preparing for the potential launches of multiple new high-impact therapies, advancing its late-stage pipeline, and leveraging its research and development (R&D) capabilities to grow its early-stage pipeline.